Zacks Nachrichten

 

Mobileye beats Q1 estimates on strong EyeQ shipments, raises 2026 outlook and approves $250M buyback....

BMY heads into Q1 earnings with strong growth portfolio momentum, but legacy drug declines and generic pressure may weigh on overall revenue performance....

Gentex beats Q1 estimates as sales jump 17% on VOXX boost and advanced features, despite tariff pressures....

CNC gears up for Q1 results with earnings seen plunging 36% despite modest revenue growth, as rising medical costs and shrinking memberships weigh....

WEX's Q1 adjusted EPS beat estimates as Benefits led revenue growth and total volume rose 7.5%, prompting higher 2026 guidance on fuel-price assumptions....

Low-leverage stocks like NVIDIA gain appeal as oil prices surge and volatility spikes, offering stability and growth amid geopolitical and rate uncertainty....

Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion....

DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins....

TEM nears profitability as gross profit surges and EBITDA turns positive, but persistent GAAP losses keep focus on long-term operating leverage....

TSLA slides despite a Q1 earnings beat as a $5B capex hike tied to AI and Robotaxi ambitions rattles sentiment, pushing investors toward ETF consideration....

ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now....

Solid retention, renewals, prudent pricing, exposure growth, and improved digitization are expected to help AXS, PLMR, AIZ, and AJG outperform first-quarter estimates....

Robert Half's Q1 EPS met estimates as talent solutions trends strengthened into early April, despite a revenue dip and a sharply higher tax rate....

Intuitive Surgical's strong Q1 results, rising procedures, and raised outlook highlight accelerating growth, while Boston Scientific faces headwinds and tempered guidance....

SLB beats Q1 revenues and EPS estimates as Digital revenues rises 9% and ChampionX contributes, while the Middle East conflict disrupts key segments....

DIT's fiscal Q2 loss per share widens year over year to $2.34 even as sales rise 16%, aided by strong distribution demand, with higher labor costs weighing on margins....

When the headlines and the market tell different stories, trust the market. We're on track for a sixth straight quarter of double-digit earnings growth, and Dave Bartosiak can guide you to stocks with positive surprises and rising estimate revisions....

Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth....

AI optimism and easing volatility fuel a $48.7B surge into global equity funds. Here are some global ETFs to consider....

RL's "Next Great Chapter" drives 10% revenue growth, powered by Asia strength and AUR gains, while boosting margin outlook for fiscal 2026....